Global First Approval For Takeda's Dengue Vaccine, In Indonesia

Set To Open Door To Wider Vaccine Use?

25 Aug 2022

Takeda’s dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to market a vaccine outside Japan and potentially paving the way to wider global use of vaccines for the mosquito-borne disease following setbacks for earlier contenders.

Takeda's Qdenga, also known as TAK-003, received its global first approval — Takeda's Qdenga awaiting regulatory approval in Europe and the US • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.’s live, attenuated tetravalent dengue vaccine Qdenga (TAK-003) has received its global first approval, in Indonesia, for the prevention of disease caused by any serotype in individuals aged six to 45 years of age.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.